Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Cancer Res. 2015 Dec 17;76(1):117–126. doi: 10.1158/0008-5472.CAN-15-0694

Fig. 7. Proposed model of sorafenib-induced keratinocyte injury.

Fig. 7

Schematic showing that sorafenib enters the keratinocyte through OAT6 and subsequently inhibits TAK1, leading to cytotoxicity and keratinocyte injury. These effects are blocked by the OAT6 inhibitor probenecid.